---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-072258"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:17:44.364064+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galecto reports positive Phase 2a myelofibrosis data; fibrosis reduction in 6 of 10 evaluable patients

## Summary
- 6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.
- All 6 patients with fibrosis reduction maintained stable hematological parameters (hemoglobin, WBC, platelets).
- One patient achieved ≥35% spleen volume reduction; two reduced Total Symptom Score >50%; one had anemia response.
- Four patients entered extension due to clinical benefit; one on treatment >30 months; GI adverse events manageable.
- Company will not decide on further GB2064 trials until completion of strategic alternative process.

## SEC filing metadata
- accession: 0000950170-23-072258
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/0000950170-23-072258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/glto-20231221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-072258
- JSON: https://secwatch.observer/filing/0000950170-23-072258.json
- Plain text: https://secwatch.observer/filing/0000950170-23-072258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.